AR7，25MG，SML0921-25MG，Sigma

Application

AR7 has been used:

• as chaperone-mediated autophagy (CMA) activator to study the activity of CMA in rat liver lysosomes
• as a CMA activator to study its effects on expression of DEAD-box helicase 3 X-linked (DDX3X), eukaryotic translation initiation factor 4A1 (EIF4A1), and eukaryotic translation initiation factor 4H (EIF4H) in cancer cells
• to study its effects on synuclein α (SNCA) oligomer levels in mature primary cortical neurons

Biochem/physiol Actions

AR7 is an atypical retinoic acid receptor α (RARα) antagonist.
AR7 is an atypical retinoic acid receptor α (RARα) antagonist. There is high interest in retinoic acid receptors for cancer and for differentiation studies. Recently, it has been found that signaling through retinoic acid receptor α (RARα) inhibits chaperone-mediated autophagy (CMA). Disruption of RARα signaling has a stimulatory effect on CMA, but can lead to inhibition of macroautophagy. AR7 antagonizes only the CMA inhibitory effect without affecting macroautophagy, allowing the two RARα effects on autophagy to be studied independently.